Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKnight Therapeutics Inc.

Knight Therapeutics Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
11.28 CAD 0.02 ( 0.18%)
Last update at 2026-11-04T20:32:00Z
VOLUME
55567
Market Cap
736.73M

Momentum Score

…

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.90
Low
11.31
High
52 Week Price Range
5.50
Low
7.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Knight Therapeutics is a Canadian specialty pharmaceutical company that in-licenses, acquires and commercializes branded medicines in Canada and select international markets, with emphasis on hospital and specialty therapeutic areas. Long-term growth may be driven by new licensing and acquisition deals, expansion of marketed product sales and specialty drug launches, and the asset-light commercialization model could support cash generation from revenues.
Principal risks include dependence on a concentrated portfolio of in-licensed products and partner agreements, execution risk in launches and market expansion, regulatory and reimbursement uncertainty, and competitive pressure on pricing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.26
Dividend Yield
-
Revenue TTM
450.09M
Revenue Per Share
4.52
Gross Profit TTM
200.23M
Debt / Equity
0.10
ROE
-0.69%
Net Debt
1.46M
ROCE
-0.25%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.70M 2.05M -21.99M -43.96M 6.69M
Net income -5.37M 4.33M -16.84M -29.89M 15.68M
Selling general administrative 124.11M 99.35M 37.41M 40.15M 37.16M
Selling and marketing expenses - - 46.28M 48.47M 37.22M
Gross profit 150.74M 174.41M 107.61M 138.06M 115.41M
Reconciled depreciation 56.57M - - - -
Ebit -2.20M - 6.43M -2.40M -5.32M
Ebitda 54.37M - 56.82M 60.22M 42.59M
Depreciation and amortization 56.57M - 50.40M 62.62M 47.91M
Operating income -2.20M 7.40M 6.43M -2.40M -5.32M
Other operating expenses 452.29M - 321.77M 310.62M 256.31M
Interest expense 10.42M - 12.49M 6.60M 3.62M
Tax provision -1.33M -2.28M -5.15M -14.07M -
Interest income 6.21M 16.23M 28.50M 15.76M -
Net interest income -4.22M - - - -
Income tax expense -1.33M - -5.15M -14.07M -8.98M
Total revenue 450.09M 371.30M 328.20M 293.56M 243.48M
Total operating expenses 152.94M - 101.19M 155.12M 128.24M
Cost of revenue 299.35M 196.90M 220.59M 155.50M 128.07M
Total other income expense net -4.50M - -28.41M -41.56M 12.01M
Net income from continuing ops -5.37M - - - -
Net income applicable to common shares - 4.33M -16.84M -29.89M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1046.30M 963.80M 945.49M 1054.84M 991.89M
Intangible assets 379.51M 283.61M 289.96M 338.78M 350.30M
Other current assets 25.45M 0.00M 20.63M 1.70M 4.51M
Total liab 279.03M 168.69M 198.62M 228.98M 149.87M
Total stockholder equity 767.27M 795.11M 746.87M 825.86M 842.02M
Other current liab 24.26M - 7.90M 15.01M 11.72M
Common stock 530.14M 534.27M 540.05M 599.05M 628.85M
Capital stock 530.14M - - 599.05M 628.85M
Retained earnings 148.94M 154.91M 150.89M 161.75M 191.65M
Other liab - - - - 31.89M
Good will 89.98M 86.48M 79.84M 82.27M 75.40M
Other assets - 28.46M - 15.60M 57.05M
Cash 76.45M 74.99M 58.76M 71.68M 85.96M
Cash and equivalents - 5.11M - 0.30M 9.03M
Total current liabilities 165.26M 111.25M 114.03M 141.32M 105.30M
Current deferred revenue - - 1.18M - -
Net debt 1.46M - 10.33M 6.02M -45.01M
Short term debt 20.13M 0.00M 19.58M 20.25M 28.28M
Short long term debt 16.73M - - 17.67M 26.66M
Short long term debt total 77.91M - 69.09M 77.70M 40.96M
Other stockholder equity 32.45M 79.99M 25.99M 23.78M 21.89M
Property plant equipment - 20.02M - 22.63M 29.94M
Total current assets 394.83M 396.81M 365.12M 395.62M 307.32M
Long term investments 79.48M - - 158.02M 178.95M
Net tangible assets - - - - 416.32M
Short term investments 18.83M 83.02M 95.66M 119.54M 77.03M
Net receivables 138.24M 105.20M 98.23M 110.20M 67.41M
Long term debt 51.16M 25.90M - 52.40M 9.27M
Inventory 135.87M 102.70M 91.83M 92.49M 72.40M
Accounts payable 120.87M - 85.37M 106.06M 65.31M
Accumulated other comprehensive income 55.74M - 29.95M 41.27M -0.38M
Non currrent assets other 8.88M - 7.77M 48.20M 47.93M
Non current assets total 651.46M - 580.38M 659.22M 684.57M
Capital lease obligations 10.02M - - 7.63M 5.03M
Long term debt total - 29.33M - 57.45M 12.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 50.99M - - - -
Total cashflows from investing activities -84.11M 16.96M 29.34M -63.08M -
Net borrowings 20.52M - - - -
Total cash from financing activities 13.01M -33.54M -71.12M 1.76M -78.31M
Net income -5.37M 4.33M -16.84M -29.89M 15.68M
Change in cash -3.66M 21.34M -12.92M -14.28M -143.63M
Begin period cash flow 80.11M - 71.68M 85.96M 229.59M
End period cash flow 76.45M - 58.76M 71.68M 85.96M
Total cash from operating activities 70.30M 36.28M 28.49M 40.48M 44.62M
Depreciation 56.57M 53.11M 50.40M 62.62M 47.91M
Other cashflows from investing activities 17.60M 48.44M 39.30M -37.26M -
Dividends paid 0.00M - - - -
Change to inventory -17.82M - 0.70M -11.43M -17.19M
Change to account receivables -26.53M - 5.58M -26.42M 8.59M
Sale purchase of stock -6.35M -8.29M -53.48M -30.07M -64.42M
Other cashflows from financing activities -4.34M -7.20M -2.85M 52.12M 9.72M
Capital expenditures 1.91M 31.47M 9.96M 25.82M 224.18M
Change in working capital 1.89M -19.62M -28.01M -9.99M 0.63M
Stock based compensation 8.11M - 2.33M 1.89M 3.04M
Other non cash items 21.03M - 29.74M 32.98M -15.01M
Free cash flow 68.40M - 18.54M 14.66M -179.56M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GUD
Knight Therapeutics Inc.		 0.02
0.18%		 11.28 - 48.54 1.64 0.96 1.60 11.97
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Knight Therapeutics Inc.

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

100 Boul. Alexis-Nihon, Montreal, QC, Canada, H4M 2P2

514-484-4483

https://www.knighttx.com

830

Name Title Year Born
Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA Exec. Chairman 1969
Ms. Samira Sakhia BCom, CA, CPA, MBA Pres, CEO & Director 1968
Mr. Arvind Utchanah Chief Financial Officer NA
Ms. Amal Khouri B.Sc., M.B.A. Chief Bus. Officer NA
Mr. Jeff Martens Global VP Commercial NA
Mr. Leopoldo Bosano Vice-Pres of Manufacturing & Operations NA
Ms. Daniela Marino Global VP of Legal & Compliance NA
Ms. Susan Caroline Emblem Global VP of HR NA
Ms. Jody Engel Sr. Director of Bus. Devel. NA
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. Executive Chairman 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…